Technology News and Research

RSS

Medtronic fourth quarter revenue increases 4% to $4.297 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 27, 2012.

From Medtronic 22 May 2012

GE Healthcare, KUH partner to drive advances in cell therapy technologies

Karolinska University Hospital Sweden and GE Healthcare Life Sciences today announced a joint research collaboration to drive advances in technologies and workflows for use in the rapidly emerging field of cell therapy.

22 May 2012

Inexpensive sleep disorder drug appears to be potent inhibitor of cancer cells

An inexpensive "orphan drug" used to treat sleep disorders appears to be a potent inhibitor of cancer cells, according to a new study led by scientists at Fred Hutchinson Cancer Research Center.

22 May 2012

“Sandwich” immunoassay used to search for new chemical reactions

Many discoveries are made by chance, but it is also possible to help it along: The chance of finding something interesting increases when the number of experiments rises. French researchers have now applied this principle to the search for new chemical reactions. In the journal Angewandte Chemie, they have introduced a new concept based on antibodies and a “sandwich” immunoassay.

22 May 2012

Studies of technological innovations presented at DDW annual meeting

Studies of technological innovations being presented for the first time at Digestive Disease Week- (DDW) showed increased accuracy coupled with decreased cost, time or invasiveness of gastrointestinal procedures. Use of a new high-definition colonoscope, for example, improved physician confidence in diagnosing small polyps, potentially reducing the amount of polyps sent for pathology analysis and the associated costs.

From Evident Corporation - Life Sciences 22 May 2012

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.

22 May 2012

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.

22 May 2012

Polarization Gating Spectroscopy may detect pancreatic cancer

By simply shining a tiny light within the small intestine, close to that organ's junction with the pancreas, physicians at Mayo Clinic's campus in Florida have been able to detect pancreatic cancer 100 percent of the time in a small study.

22 May 2012

FSU announces availability of Pacifier Activated Lullaby device

Many premature babies enter the world with a mountain of challenges in front of them. Even after they overcome any life-threatening issues, they face ongoing, and typically unpleasant, medical procedures, long hospital stays and increased chances of chronic health issues throughout their lives.

22 May 2012

TransCytos, Enginasion collaborate to develop new transfection technology

Enginasion and TransCytos announced today that their collaboration has resulted in a prototype 'transfection' technology that is designed to have a dramatic and positive impact on the drug-research industry.

22 May 2012

FDA clears Teleflex’s ARROW PICC with Chloragard technology

Teleflex Incorporated announced today that in addition to broad-spectrum antimicrobial protection, the pressure-injectable ARROW PICC with Chloragard Technology provides antithrombogenic protection for at least 30 days.

22 May 2012

CSA Medical unveils new truFreeze Spray Cryotherapy System

CSA Medical, Inc. unveiled the new truFreeze Spray Cryotherapy System this week at the Digestive Disease Week (DDW) 2012 Annual Meeting in San Diego.

21 May 2012

Male cyclists may experience hormonal imbalances that affect reproductive health

A new study conducted by UCLA School of Nursing researchers has found that serious leisure male cyclists may experience hormonal imbalances that could affect their reproductive health. The study, "Reproductive Hormones and Interleukin-6 in Serious Leisure Male Athletes," was published in the European Journal of Applied Physiology.

21 May 2012

New optical microscope sees individual blood cells as they flow inside the body

Blood tests convey vital medical information, but the sight of a needle often causes anxiety and results take time. A new device developed by a team of researchers in Israel, however, can reveal much the same information as traditional blood test in real-time, simply by shining a light through the skin.

21 May 2012

New trial on home oxygen therapy for patients with chronic heart failure

Researchers at the University of Hull, in the UK, have just launched a major new trial investigating the effects of home oxygen therapy in patients with chronic heart failure (CHF).

21 May 2012

Regenerative medicine researchers explore innovative ways to treat childhood conditions

About 3 percent of the babies born in the United States have a birth defect. Children without a birth defect are also susceptible to injury or disease. At The University of Texas Health Science Center at Houston (UTHealth), regenerative medicine researchers are exploring innovative ways to treat these conditions.

21 May 2012

Aushon plans global launch of new multiplex protein biomarker platform

Aushon announced its plans today for an upcoming global launch of its new multiplex protein biomarker platform, which incorporates several engineering breakthroughs to deliver ELISA-level performance.

21 May 2012

Cook Medical introduces drug-eluting peripheral stent to treat lesions in the SFA

Cook Medical, a world leader in minimally invasive medical technologies, has launched a first-of-its-kind drug-eluting peripheral stent in Australia, the Zilver PTX Drug-Eluting Peripheral Stent.

21 May 2012

New supplements safety guide for athletes

The U.S. Anti-Doping Agency (USADA) recently released a new supplements safety guide for athletes as part of their "Supplement 411" initiative.

21 May 2012

SERVE-HF study on effect of CSA treatment for stable heart failure enrolls 1,000th participant

SERVE-HF, the largest study to investigate if treatment of predominant central sleep apnea (CSA) improves survival and outcomes of patients with stable heart failure, has enrolled its 1,000th participant. The study, sponsored by ResMed Ltd., is the largest of its kind. This milestone brings the SERVE-HF study, which began in 2008, one step closer to its target of approximately 1,250 participants.

From ResMed Corp 21 May 2012